Alzheimer’s Blood Test for Early Detection

MedDevice by Design with Mark Drlik and Ariana Wilson
Resources

Alzheimer’s Blood Test for Early Detection

Sector: Diagnostics
YouTube video thumbnail

In this episode of MedDevice by Design, we explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.

A Simpler Diagnostic Pathway

Traditionally, Alzheimer’s diagnosis has required expensive imaging or invasive cerebrospinal fluid collection. This new approach allows patients to have their blood drawn at a standard medical office, with labs analyzing the sample for specific biomarkers. If these proteins are detected, the patient may then be referred for confirmatory tests and begin treatment earlier.

Supporting Earlier Treatment and Better Research

Early detection is crucial for effective treatment. Many Alzheimer’s drugs are more beneficial when administered during the disease’s early stages. This blood test can identify potential patients sooner, improving clinical outcomes. It also helps pharmaceutical companies recruit participants for trials and monitor drug efficacy over time.

Barriers to Widespread Use

While promising, the Alzheimer’s blood test still faces some hurdles. It’s currently a laboratory-developed test (LDT) and has not yet received FDA approval. Because of this, it’s often not covered by insurance and remains a costly out-of-pocket option for most people.

A Look Ahead

The potential impact of this innovation is immense. By making early Alzheimer’s detection more accessible, the test could transform clinical care and research. As approval processes advance and accessibility improves, this technology may reshape how we diagnose and treat neurodegenerative conditions.

Medical device pilot manufacturing workspace showing engineers supporting NPI and scalable production

In MedTech, success rarely comes from invention alone. Plenty of promising technologies make it through verification and early clinical work, only to stall when the team tries to turn them into something buildable.

Thumbnail showing bacterial growth from one cell to 10²¹ cells, illustrating rapid bacteria reproduction with text reading “This fast?” and a red arrow indicating exponential increase.

From how much of your body is actually bacterial to how fast microbes can multiply, these facts are designed to stick with you long after the party ends.

Engineer reviewing a systems workflow diagram representing proportional verification planning in medical device development

In medical device development, verification is both a safeguard and a stress test, not just for the product, but for the process.

Cross-functional MedTech team discussing requirements on a tablet during a medical device development meeting.

In the world of medical device development, requirements are often treated as a regulatory tax, essentially documentation created solely to satisfy a compliance need.